Monopar Therapeutics (MNPR) Other Working Capital Changes: 2017-2020
Historic Other Working Capital Changes for Monopar Therapeutics (MNPR) over the last 4 years, with Sep 2020 value amounting to $76,609.
- Monopar Therapeutics' Other Working Capital Changes rose 926.24% to $76,609 in Q3 2020 from the same period last year, while for Sep 2020 it was -$59,419, marking a year-over-year increase of 46.80%. This contributed to the annual value of $21,792 for FY2024, which is 6.77% up from last year.
- As of Q3 2020, Monopar Therapeutics' Other Working Capital Changes stood at $76,609, which was up 146.62% from -$164,342 recorded in Q2 2020.
- Over the past 5 years, Monopar Therapeutics' Other Working Capital Changes peaked at $139,557 during Q4 2017, and registered a low of -$164,342 during Q2 2020.
- Moreover, its 3-year median value for Other Working Capital Changes was $21,365 (2019), whereas its average is -$4,632.
- In the last 5 years, Monopar Therapeutics' Other Working Capital Changes skyrocketed by 2,528.11% in 2018 and then plummeted by 2,102.09% in 2020.
- Over the past 4 years, Monopar Therapeutics' Other Working Capital Changes (Quarterly) stood at $139,557 in 2017, then plummeted by 183.36% to -$116,330 in 2018, then skyrocketed by 88.16% to -$13,770 in 2019, then skyrocketed by 926.24% to $76,609 in 2020.
- Its Other Working Capital Changes was $76,609 in Q3 2020, compared to -$164,342 in Q2 2020 and $42,084 in Q1 2020.